In­vestors throw $189M at Flag­ship star­tup's mis­sion to 'de­code' in­ter­ac­tions be­tween T cells and anti­gens

Two is of­ten bet­ter than one in the world of bio­phar­ma in­vest­ment. If you need proof, look no fur­ther than Reper­toire Im­mune Med­i­cines.

Reper­toire launched last March out of a merg­er be­tween Flag­ship star­tups Co­gen Im­mune Med­i­cines and Torque Ther­a­peu­tics. And ear­ly Tues­day morn­ing, the team un­cloaked a mas­sive $189 mil­lion Se­ries B round to fund its mis­sion to de­code the in­ter­ac­tions be­tween T cells and anti­gens.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER